Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
24,445 total articles
TELA Bio reported Q1 2026 revenue of $19.1 million, a 3% increase over the previous year, driven by robust international sales and product unit growth. The company launched OviTex LTR in the US, a fully resorbable hernia repair solution, and is expanding its European presence with 41% revenue growth. Despite a net loss increasing slightly to $12.3 …
Datadog, Inc., a leading AI-powered observability and security platform, announced that its management team will present at three prestigious investor conferences between May and June 2026. The presentations will be webcast live and later made available on the company's investor relations website.
Phillips Edison & Company, a leading US owner and operator of grocery-anchored neighborhood shopping centers, declared monthly dividend distributions of $0.1083 per common share payable in July and August 2026. Additionally, at their virtual annual meeting, all directors were re-elected, executive compensation was approved advisory-wise, and Deloit…
Mobile Infrastructure Corporation reported Q1 2026 financial results highlighting stable same-location revenue and a 4.4% increase in same-location net operating income (NOI), driven by improved parking utilization and contract volume growth. The company progressed in its $100 million asset rotation program with over $30 million in asset sales, use…
LB Pharmaceuticals announced Q1 2026 financial results and corporate updates highlighting initiation of pivotal Phase 3 trial for LB-102 in schizophrenia and Phase 2 trial in bipolar depression. The company secured $100 million in a private placement to fund operations into 2029, supporting multiple planned clinical readouts potentially unlocking s…
Reed's, Inc. reported a challenging first quarter of 2026 with net sales declining to $7.1 million from $10 million a year earlier, gross margin compression from 34% to 10%, and a net loss rising to $6.5 million. The company cited inventory rationalization, elevated SG&A expenses, and softer sales execution as key factors impacting results. Leaders…
High Roller Technologies announced strategic initiatives to launch ROLR-branded prediction markets in the U.S., backed by a definitive agreement with Crypto.com | Derivatives North America, strategic marketing partnerships, and enhanced applied AI capabilities. The company reported Q1 2026 revenues of $3.4 million, improved adjusted EBITDA, reduced…
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company focused on treating inflammatory diseases such as asthma and COPD, announced its management will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference. The company is advancing its lead drug candidate rademikibart, currently in global clini…
Bolt Biotherapeutics, a clinical-stage biopharmaceutical company focused on innovative cancer immunotherapies, reported its Q1 2026 financial results and business update. The company is advancing its lead product BDC-4182, a novel immune-stimulating antibody conjugate (ISAC) targeting claudin 18.2 for gastric and gastroesophageal cancers, with init…
Hour Loop, Inc., a U.S.-based online retailer, announced its Q1 2026 financial results showing a 16% year-over-year increase in net revenues to $29.9 million, with net income rising to $0.82 million. The company attributed revenue growth to expanded inventory availability and strong sales execution, despite a modest decline in gross margin due to h…
Surrozen, Inc., a biotechnology company specializing in targeted Wnt signaling therapeutics for ophthalmic diseases, announced that its management will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The presentation will be available via webcast and will outline the company's research, development plans, a…
Nurix Therapeutics announced that updated efficacy and safety data from their ongoing Phase 1a/b trial of the BTK degrader bexobrutideg (NX-5948) in chronic lymphocytic leukemia patients will be presented orally at the 31st Congress of the European Hematology Association. The drug is currently being evaluated in pivotal Phase 2 and Phase 1a/b clini…
XBP Global Holdings, Inc. has scheduled a conference call and webcast for May 14, 2026, to discuss its first quarter 2026 financial results. The company, a multinational technology and services provider specializing in hyper-automation and digital transformation, will issue a press release after market close on the same day. Management will host th…
PEDEVCO Corp., a publicly traded energy company specializing in oil and gas asset acquisition and development in the Rocky Mountain region, announced its participation in the LD Micro Invitational XVI Conference. The management team will present and engage with investors during the event held from May 17-19, 2026 in Los Angeles. The conference serv…
GrowGeneration Corp. announced its first quarter 2026 financial results, reporting a 7.5% year-over-year increase in net sales to $38.4 million, along with a significant improvement in net loss by $4.5 million to $4.9 million. The company experienced increased proprietary brand penetration to 37% of cultivation and gardening revenue and improved ad…
Lumexa Imaging announced the addition of four new outpatient imaging centers in four U.S. locations as part of its multi-channel growth strategy, including acquisitions with joint venture partners Advocate Health and UPMC. The company now operates over 190 outpatient centers nationwide and plans to continue expansion through de novo developments, a…
Capricor Therapeutics reports first quarter 2026 financial results with a net loss of $33.9 million and a cash balance of approximately $279 million, supporting operations into Q4 2027. The company's Biologics License Application (BLA) for Deramiocel, a potential treatment for Duchenne muscular dystrophy (DMD), is under active FDA review with a PDU…
CNB Financial Corporation announced a quarterly cash dividend of $0.19 per share payable on June 15, 2026, to shareholders of record as of June 1, 2026. The company operates primarily through its subsidiary CNB Bank, which offers comprehensive banking services across multiple states including Pennsylvania, Ohio, New York, and Virginia.
Sana Biotechnology announced preclinical data showing its in vivo CAR T cell therapy candidate SG293 achieves targeted and potent CAR T cell generation and effective B cell depletion in non-human primates without lymphodepleting chemotherapy. The data supports advancing SG293 into clinical trials for non-Hodgkin lymphoma later this year and SG227 f…
Fractyl Health announced its first quarter 2026 financial results and provided updates on its lead metabolic therapeutics programs: Revita, a procedural therapy for post-GLP-1 weight maintenance, and Rejuva, a gene therapy platform targeting type 2 diabetes. The company remains on track for key 2026 clinical data readouts, including pivotal REMAIN-…
Lifecore Biomedical, a US-based injectable CDMO, announced its participation in the CDMO Live Europe conference held in Rotterdam. The company will engage in panel discussions and meetings to present its capabilities in sterile injectable pharmaceutical product development and manufacturing, focusing on process development and manufacturing service…
Espey Mfg. & Electronics Corp. reported third quarter fiscal 2026 results showing higher net income and earnings per share compared to the prior year quarter despite a slight decline in nine-month sales and new orders. The company highlights strong backlog and a focus on margin expansion through favorable product mix, operational leverage, and cost…
Neumora Therapeutics, a clinical-stage biopharmaceutical company focusing on novel neuroscience drug development, announced it will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on May 19, 2026. The event will be webcast live and archived for up to 30 days.
Nyxoah SA announced its Q1 2026 financial results highlighted by a robust 25% sequential growth in U.S. net revenue owing to the strong commercial launch of its Genio hypoglossal neurostimulation system for obstructive sleep apnea (OSA). The company continues to gain surgeon trainees and account activations, alongside achieving 100% prior authoriza…
Red Cat Holdings, a U.S.-based defense and national security drone and robotic solutions provider, has announced a proposed underwritten public offering of $200 million in common stock with an option for underwriters to purchase an additional $30 million. The proceeds will be used for general corporate purposes including acquisitions, R&D, capital …
